SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is generating significant community attention following an upbeat revenue forecast and an upward revision to its annual delivery guidance, which has fueled a debate over whether these positive operational updates justify recent share dilution or if the stock remains a high-volatility trading vehicle. Investors are heavily focused on the company's scaling potential and the upcoming R2 launch, while discussions remain polarized between long-term bulls betting on a fundamental turnaround and skeptical traders concerned about the repeated pattern of capital raises capping rally momentum.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors weigh conflicting signals between reports of potential product delays and the company's firm rebuttal that its AI infrastructure roadmap remains intact. Market sentiment is heavily divided, with some community members frustrated by the stock's recent volatility and alleged price manipulation, while others maintain conviction in the long-term fundamentals of the AI compute cycle.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is currently trending due to positive Phase 3 trial data for its COMP360 therapy, which demonstrates durable therapeutic benefits and a strong safety profile. Investors are actively discussing the company's regulatory momentum following FDA support for a rolling NDA submission, while clinical milestone catalysts and potential for breakthrough treatment in depression continue to drive community enthusiasm.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The firm's product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is trending following a massive $10 billion acquisition by Vertex Pharmaceuticals, a deal that represents a significant premium for shareholders. Investors are now actively debating whether to lock in gains or monitor the stock for potential merger arbitrage opportunities as the sector continues to see intense M&A activity.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is facing intense volatility as traders debate whether the current semiconductor pullback is a temporary buying opportunity for the AI cycle or the beginning of a deeper trend reversal. The community is sharply divided, with many actively trading the aggressive swings while others warn of technical breakdown and further downside risk.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is experiencing significant volatility following the completion of its Alkira acquisition, which aims to integrate software-defined networking into its AI-focused fiber infrastructure. While management positions this as a strategic pivot toward higher-margin software services, investors are actively debating whether this heavy capital expenditure strategy will deliver on promised revenue inflection points or continue to burden the balance sheet.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as a broader semiconductor sell-off, sparked by Samsung's earnings and concerns over AI cycle sustainability, triggers heavy volatility. Investors are actively debating whether this pullback is a temporary reset for long-term growth or the beginning of a larger correction, with many retail participants discussing whether to capitalize on the dip or brace for further downside.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is currently seeing heightened investor interest driven by a significant price target hike from Goldman Sachs and strategic partnerships, including new collaborations in autonomous driving. While the broader semiconductor sector remains volatile due to concerns over AI-cycle sustainability, the community remains actively divided between bullish sentiment regarding the company's data center and AI compute roadmap and bearish concerns about stretched valuations.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals is in the spotlight following the announcement of a definitive agreement to acquire Crinetics Pharmaceuticals for $10 billion, a move the market views as a significant strategic expansion into the lucrative endocrinology space. Community discussion is heavily focused on the 102% acquisition premium, with many investors debating the long-term growth potential of the acquired assets versus the high cost of the deal.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing significant volatility as investors debate whether the current pullback is a healthy consolidation within a long-term memory supercycle or a signal that the AI-driven rally has peaked. Community sentiment remains deeply divided, with many traders viewing the dip as a prime buying opportunity supported by strong earnings potential, while others fear further downside pressure amid concerns over global memory production capacity and institutional profit-taking.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tiziana Life Sciences Stock Rises Over 9% After Multiple Sclerosis Trial Enrollment Update

Equity

The biotechnology company has completed enrollment in its placebo-controlled study of intranasal foralumab, with late-stage data expected in 2026.

Wall Street Zen Downgrades Tiziana Life Sciences (NASDAQ:TLSA) to Sell

Wall Street Zen lowered Tiziana Life Sciences from a "hold" rating to a "sell" rating in a research note on Saturday...

Tiziana Life Sciences (NASDAQ:TLSA) Trading 6.8% Higher - Here's What Happened

Tiziana Life Sciences (NASDAQ:TLSA) Trading 6.8% Higher - Here's What Happened...

Tiziana Life Sciences Stock Jumps As Positive Preclinical Fuels Momentum

Tiziana Life Sciences shares jump on intranasal foralumab data, while technical indicators point to mixed momentum.read more...

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 4.4% - Should You Sell?

Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 4.4% - Should You Sell...

Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 0.7% - Here's What Happened

Tiziana Life Sciences (NASDAQ:TLSA) Shares Up 0.7% - Should You Buy...

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 3.1% - Should You Buy?

Tiziana Life Sciences (NASDAQ:TLSA) Trading 3.1% Higher - Still a Buy...

Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 7.4% - Still a Buy?

Tiziana Life Sciences (NASDAQ:TLSA) Shares Up 7.4% - What's Next...

Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 4.4% - Here's Why

Tiziana Life Sciences (NASDAQ:TLSA) Shares Down 4.4% - Should You Sell...

Tiziana Life Sciences (NASDAQ:TLSA) Shares Down 4.5% - Here's Why

Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 4.5% - Here's What Happened...

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Alzheimer’s. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

Tiziana Life Sciences Ltd

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

TLSATiziana Life Sciences Ltd

Fundamentals

Latest TLSA News